Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Saved in:
Bibliographic Details
Title: Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
Authors: Kim DK; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Synn CB; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee W; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Jo HN; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee CY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea., Hwang JY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim Y; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kang SS; JEUK Institute for Cancer Research, JEUK Co., Ltd., Gumi-City, Republic of Korea., Baek S; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Na K; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Yang SM; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim MH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han H; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Han YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim JH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Park SY; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Park YJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee GT; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Choi SJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Sohn JO; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea., Ye SK; Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea.; Department of Pharmacology and Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea., Lee JB; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Lim SM; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Hong MH; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Pyo KH; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.; Department of Research Support, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Cho BC; Division of Medical Oncology, Department of Internal Medicine and Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.; Yonsei New Il Han Institute for Integrative Lung Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2025 Mar 04; Vol. 24 (3), pp. 354-369.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-24-0501